fashion -WSS

fashion

author：entertainment 2025-09-27 09:46:55 - browse：9946

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

Wikipedia

focus

WSS

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Beware the threat of staffing cuts at the CDC

Innovation in antibiotics is ailing. 'Brain drain' may kill it

The boys, now 6, who are gene therapy’s ‘edge case’ problem

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Innovation in antibiotics is ailing. 'Brain drain' may kill it

explore

fashion

Wikipedia

Medicare details structure of new drug price negotiation program

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Guidelines to prevent youth baseball injuries need more muscle

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Medicare proposal to cover medical devices draws a mixed reaction

Ionis drug prevents swelling attacks due to hereditary angioedema

Psychedelics group wrestles with new pharma identity

Liz Cheney makes 1st public comment since Trump's election interference indictments

23andMe had bad news about my health. I wish a person had delivered it

New details revealed about Purdue's marketing of OxyContin

explore

Evacuations in place as 3 wildfires burn in eastern Washington state

Living with Hashimoto's and celiac disease, and med school, too

Change Healthcare can notify patients about the breach, HHS says

As Maui death toll rises, number of missing remains unclear

The boys, now 6, who are gene therapy’s ‘edge case’ problem

An interview with Robert F. Kennedy Jr. on vaccines

hotspot

Wikipedia

focus

entertainment